Universität zu Köln

Furman, Richard R., Sharman, Jeff P., Coutre, Steven E., Cheson, Bruce D., Pagel, John M., Hillmen, Peter, Barrientos, Jacqueline C., Zelenetz, Andrew D., Kipps, Thomas J., Flinn, Ian ORCID: 0000-0001-6724-290X, Ghia, Paolo ORCID: 0000-0003-3750-7342, Eradat, Herbert, Ervin, Thomas, Lamanna, Nicole ORCID: 0000-0003-3331-9491, Coiffier, Bertrand, Pettitt, Andrew R., Ma, Shuo, Stilgenbauer, Stephan, Cramer, Paula, Aiello, Maria, Johnson, Dave M., Miller, Langdon L., Li, Daniel, Jahn, Thomas M., Dansey, Roger D., Hallek, Michael and O'Brien, Susan M. (2014). Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia. N. Engl. J. Med., 370 (11). S. 997 - 1008. WALTHAM: MASSACHUSETTS MEDICAL SOC. ISSN 1533-4406

Furman, Richard R., Sharman, Jeff P., Coutre, Steven E., Cheson, Bruce D., Pagel, John M., Hillmen, Peter, Barrientos, Jacqueline C., Zelenetz, Andrew D., Kipps, Thomas J., Flinn, Ian, Ghia, Paolo ORCID: 0000-0003-3750-7342, Eradat, Herbert, Ervin, Thomas, Lamanna, Nicole ORCID: 0000-0003-3331-9491, Hallek, Michael, Coiffier, Bertrand, Pettitt, Andrew R., Ma, Shuo, Stilgenbauer, Stephan, Cramer, Paula, Aiello, Maria, Johnson, Dave M., Miller, Langdon L., Li, Daniel, Jahn, Thomas M., Dansey, Roger D. and O'Brien, Susan M. (2013). A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib and Rituximab for Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL). Blood, 122 (21). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Sharman, Jeff P., Coutre, Steven E., Furman, Richard R., Cheson, Bruce D., Pagel, John M., Hillmen, Peter, Barrientos, Jacqueline C., Zelenetz, Andrew D., Kipps, Thomas J., Flinn, Ian W., Ghia, Paolo, Hallek, Michael, Coiffier, Bertrand, O'Brien, Susan, Tausch, Eugen, Kreuzer, Karl-Anton, Jiang, Wendy, Lazarov, Mirella, Li, Daniel, Jahn, Thomas M. and Stilgenbauer, Stephan (2014). Second Interim Analysis of a Phase 3 Study of Idelalisib (ZYDELIG (R)) Plus Rituximab (R) for Relapsed Chronic Lymphocytic Leukemia (CLL): Efficacy Analysis in Patient Subpopulations with Del(17p) and Other Adverse Prognostic Factors. Blood, 124 (21). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020